Eli Lilly and Company’s monoclonal antibody combination therapy was found to help prevent COVID-19 among nursing home residents and staff in a Phase 3 trial, the company announced on Thursday.
The trial included 965 participants who tested negative for the coronavirus and 132 participants who tested positive, according to the announcement.
All participants were randomly given either 4,200 milligrams of the therapy known as LY-CoV555 or a placebo.
The trial results showed that after eight weeks, the residents given LY-CoV555, also called bamlanivimab, had up to an 80% lower risk of contracting COVID-19 versus residents in the same facility who received a placebo.
During the entire trial, there were a total of 16 deaths reported, including deaths not related to COVID-19, and all deaths occurred [among] residents, according to the announcement.
Eleven of those deaths occurred among people given a placebo and five were among those given the therapy.
“We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society,” Dr. Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in a news release on Thursday.
“These data provide important additional clinical evidence regarding the use of bamlanivimab to fight COVID-19 and strengthen our conviction that monoclonal antibodies such as bamlanivimab can play a critical role in turning the tide of this pandemic,” Skovronsky said.
“We’re glad bamlanivimab is already available as a treatment for patients at high risk for progressing to severe COVID-19 illness or hospitalization, including those in nursing homes, and look forward to working with regulators to explore expanding the emergency use authorization to prevent the spread of COVID-19 in these facilities.”
In November, the US Food and Drug Administration issued an emergency use authorization for the therapy to treat mild to moderate coronavirus infections in adults and children.
The single antibody treatment is administered as an infusion in a hospital or other health care setting.